REPH Recro Pharma, Inc.

7.26
+0.16  (2%)
Previous Close 7.10
Open 7.10
Price To book 2.10
Market Cap 138.30M
Shares 19,050,000
Volume 151,721
Short Ratio 3.67
Av. Daily Volume 157,752

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data from second trial released November 28, 2016. Primary endpoint met. Safety study to be completed May 9, 2017 - NDA filing due 3Q 2017.
Intravenous (IV) meloxicam
Acute pain following bunionectomy surgery